BR112016030758B8 - Uso de células estromais multipotentes derivadas de tecido adiposo mesenquimal - Google Patents

Uso de células estromais multipotentes derivadas de tecido adiposo mesenquimal

Info

Publication number
BR112016030758B8
BR112016030758B8 BR112016030758A BR112016030758A BR112016030758B8 BR 112016030758 B8 BR112016030758 B8 BR 112016030758B8 BR 112016030758 A BR112016030758 A BR 112016030758A BR 112016030758 A BR112016030758 A BR 112016030758A BR 112016030758 B8 BR112016030758 B8 BR 112016030758B8
Authority
BR
Brazil
Prior art keywords
strome
multipotent
adipose tissue
cells derived
mesenchymal
Prior art date
Application number
BR112016030758A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112016030758B1 (pt
BR112016030758A2 (enExample
Inventor
Dalemans Wilfried
Lombardo Eleuterio
Dekker Robert
Original Assignee
Tigenix S A U
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tigenix S A U, Takeda Pharmaceuticals Co filed Critical Tigenix S A U
Publication of BR112016030758A2 publication Critical patent/BR112016030758A2/pt
Publication of BR112016030758B1 publication Critical patent/BR112016030758B1/pt
Publication of BR112016030758B8 publication Critical patent/BR112016030758B8/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0031Rectum, anus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Physiology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
BR112016030758A 2014-06-30 2015-06-30 Uso de células estromais multipotentes derivadas de tecido adiposo mesenquimal BR112016030758B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14175095.0 2014-06-30
EP14175095 2014-06-30
PCT/IB2015/054923 WO2016001846A1 (en) 2014-06-30 2015-06-30 Mesenchymal stromal cells for treating sepsis

Publications (3)

Publication Number Publication Date
BR112016030758A2 BR112016030758A2 (enExample) 2017-08-22
BR112016030758B1 BR112016030758B1 (pt) 2021-10-13
BR112016030758B8 true BR112016030758B8 (pt) 2022-10-25

Family

ID=51033023

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016030758A BR112016030758B8 (pt) 2014-06-30 2015-06-30 Uso de células estromais multipotentes derivadas de tecido adiposo mesenquimal

Country Status (14)

Country Link
US (2) US20170151284A1 (enExample)
EP (1) EP3160481B1 (enExample)
JP (1) JP6722599B2 (enExample)
KR (1) KR102213527B1 (enExample)
CN (1) CN106573017B (enExample)
AU (1) AU2015283662B2 (enExample)
BR (1) BR112016030758B8 (enExample)
CA (1) CA2953884C (enExample)
IL (1) IL249814B (enExample)
MX (1) MX381544B (enExample)
NZ (1) NZ727950A (enExample)
RU (1) RU2715866C2 (enExample)
SG (1) SG11201610844PA (enExample)
WO (1) WO2016001846A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11518982B2 (en) * 2015-12-01 2022-12-06 Adiposeeds, Inc. Method for manufacturing mesenchymal cell line derived from vertebrate animal adipose tissue
US11701389B2 (en) * 2016-03-09 2023-07-18 Emory University Methods of preserving mesenchymal stem cells
GB201604304D0 (en) * 2016-03-14 2016-04-27 Tigenix S A U Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
WO2018158542A1 (fr) 2017-02-28 2018-09-07 Université De Lorraine Cellules souches mesenchymateuses issues de la gelée de wharton pur le traitement du sepsis
WO2019084010A1 (en) 2017-10-26 2019-05-02 Emory University MCL-1 INHIBITORS, COMPOSITIONS AND USES IN CANCER CARE
JP7343091B2 (ja) * 2018-06-05 2023-09-12 メディポスト・カンパニー・リミテッド 軟骨損傷関連の疾患を処置するための、ヒアルロン酸及び幹細胞を含む医薬組成物
CA3116196A1 (en) * 2018-10-29 2020-05-07 Ottawa Hospital Research Institute Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof
US20230086254A1 (en) * 2020-01-30 2023-03-23 Jcr Pharmaceuticals Co., Ltd. Medicinal composition comprising dental pulp-derived cells
CA3220002A1 (en) * 2021-05-13 2022-11-17 Primegen Us, Inc. Methods and compositions for treating liver disease
CN113398150A (zh) * 2021-06-18 2021-09-17 卡替(上海)生物技术有限公司 牙髓间充质干细胞在脓毒症治疗中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9307550A (pt) 1992-12-02 1999-05-25 Shell Int Research Composto fungicida processo para a preparação de um composto fungicida composição fungicida processo de combate aos fungos em um local e uso
WO1995002698A1 (en) 1993-07-12 1995-01-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
US6051429A (en) 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
DE69634084T2 (de) 1995-06-07 2005-12-08 Inex Pharmaceuticals Corp. Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer
US5744335A (en) 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
US5705308A (en) 1996-09-30 1998-01-06 Eastman Kodak Company Infrared-sensitive, negative-working diazonaphthoquinone imaging composition and element
US6777231B1 (en) 1999-03-10 2004-08-17 The Regents Of The University Of California Adipose-derived stem cells and lattices
EP2298861B1 (en) * 2004-03-22 2017-09-13 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
JP5925408B2 (ja) 2005-09-23 2016-05-25 タイジェニックス、ソシエダッド、アノニマ、ウニペルソナルTigenix S.A.U. 免疫調節活性を有する細胞集団、単離方法および使用
GB0814249D0 (en) * 2008-08-04 2008-09-10 Cellerix Sa Uses of mesenchymal stem cells
CN109432126B (zh) * 2011-03-11 2022-06-14 儿童医学中心公司 与间充质干细胞外来体相关的方法和组合物
JP2014016782A (ja) * 2012-07-09 2014-01-30 Toshiba Corp 情報処理装置およびプログラム
US20140134140A1 (en) * 2012-11-09 2014-05-15 Case Western Reserve University Mesenchymal stem cell compositions for the treatment of microbial infections

Also Published As

Publication number Publication date
MX381544B (es) 2025-03-12
SG11201610844PA (en) 2017-01-27
BR112016030758B1 (pt) 2021-10-13
IL249814A0 (en) 2017-03-30
CA2953884A1 (en) 2016-01-07
CA2953884C (en) 2022-12-06
MX2017000142A (es) 2017-07-28
RU2016151738A (ru) 2018-07-30
WO2016001846A1 (en) 2016-01-07
IL249814B (en) 2020-02-27
US20170151284A1 (en) 2017-06-01
RU2715866C2 (ru) 2020-03-03
EP3160481A1 (en) 2017-05-03
KR102213527B1 (ko) 2021-02-09
AU2015283662A1 (en) 2017-01-19
JP6722599B2 (ja) 2020-07-15
NZ727950A (en) 2022-07-01
KR20170021343A (ko) 2017-02-27
US20200376038A1 (en) 2020-12-03
RU2016151738A3 (enExample) 2019-01-30
JP2017520583A (ja) 2017-07-27
BR112016030758A2 (enExample) 2017-08-22
CN106573017B (zh) 2021-06-11
EP3160481B1 (en) 2020-09-09
AU2015283662B2 (en) 2020-09-24
CN106573017A (zh) 2017-04-19

Similar Documents

Publication Publication Date Title
BR112016030758B8 (pt) Uso de células estromais multipotentes derivadas de tecido adiposo mesenquimal
MX2023010124A (es) Generacion de acido peroxiformico a traves de formiato de alcohol polihidrico.
CL2016002751A1 (es) Compuestos y composiciones como agonistas del receptor tipo toll 7.
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
MX2016002571A (es) Regulador de ph de transduccion.
BR112016025132A2 (pt) compostos polifluorados agindo como inibidores de tirosina quinase de bruton
DK3692857T3 (da) Indretning til levering af hudplejesammensætning
EA201790273A1 (ru) Флагеллиновые композиции и их применение
UY33917A (es) ?composiciones para recubrimiento que comprenden submicropartículas que comprenden carbonato de calcio, proceso para prepararlas, y uso de las submicropartículas?.
MX390739B (es) Composicion de hueso comprimido y metodo para usar la misma.
BR112018008931A8 (pt) ?compostos para tratamento de distúrbios hipoproliferativos?
MX362471B (es) Composiciones para el cuidado bucal que tienen estabilidad mejorada.
LT3250202T (lt) Kompozicija, skirta naudoti kraujodaros kamieninių ląstelių po transplantacijos prigijimo pagerinimui
DOP2016000073A (es) Composiciones y métodos para inhibir la expresión del gen alas1
MX2021000773A (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos de uso del mismo.
DK3828203T3 (da) Sammensætninger og fremgangsmåder til behandling af fedtvævsopbygning
MX2015003701A (es) Composiciones para tratamiento.
EP3387112A4 (en) METHOD FOR RECONNECTING BROWN FAT CELLS DERIVED FROM VARIOUS PLURIPOTENT STEM CELLS
DOP2017000146A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
BR112017009289A2 (pt) métodos de administrar composições de amantadina
NZ703345A (en) Compositions and methods for reducing frequency and/or severity of headache
DK3189844T3 (da) Pluripotent stamcelle til behandling af diabetisk hudsår
MX2016009655A (es) Metodos novedosos para el tratamiento del cancer.
EP3300506A4 (en) Use of mesenchymal stem cells in treating osteoarthritis
GT201500056S (es) Aparato para peinar el cabello

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/06/2015, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)